{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"3.5","value":"2.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"}],"units":"Participants"}],"description":"PFS was defined as the time from the date of first dose to the date of first documented PD or relapse or death due to any cause. PD: at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of \\>=1 new target or non-target lesions was also considered progression. PFS data was censored at date of last adequate tumor assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received an oral dose of 45 mg of binimetinib tablets (3 tablets of 15 mg) twice daily in each cycle starting from Cycle 1 Day 1 (1 cycle =28 days) until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason. Maximum treatment exposure was approximately of 19.4 months.","id":"OG000","title":"Binimetinib (MEK162)"}],"paramType":"MEDIAN","populationDescription":"Full analysis set included all the participants who had received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From the date of first dose to the date of the first documented PD, censored date or death (maximum up to 19.4 months)","title":"Progression-free Survival (PFS) as Per RECIST Version 1.1","type":"SECONDARY","unitOfMeasure":"Months"}